These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 9616891

  • 1. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J, Millet C, Levillain P, Doré B, Bégon F, Aubert J.
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [Abstract] [Full Text] [Related]

  • 2. Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
    Irani J, Salomon L, Soulié M, Zlotta A, de la Taille A, Doré B, Millet C.
    Urology; 2005 Mar; 65(3):533-7. PubMed ID: 15780371
    [Abstract] [Full Text] [Related]

  • 3. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 4. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M, Bastian M, Steiner M, Zingler C, Müller M, Wolff JM, Seiter H, Schuff-Werner P.
    Anticancer Res; 2000 Dec 15; 20(6D):4995-6. PubMed ID: 11326656
    [Abstract] [Full Text] [Related]

  • 5. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
    Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, Opsomer R, Wese FX.
    Prostate Suppl; 1996 Dec 15; 7():30-4. PubMed ID: 8950361
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar 15; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan 15; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. PSA excess in the differential diagnosis of prostate carcinoma.
    Díaz F, Morell M, Rojo G.
    Arch Esp Urol; 1997 May 15; 50(4):415-8. PubMed ID: 9219422
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W, Stieber P, Schmeller N, Nagel D, Hofmann K, Fateh-Moghadam A.
    Anticancer Res; 1997 May 15; 17(6D):4759-65. PubMed ID: 9494603
    [Abstract] [Full Text] [Related]

  • 14. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan 15; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 15. [Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer].
    Laguna Pes MP, Guinda Sevillano C, Zazo Romojaro A, Domínguez J, García Luzón A, Borrego Hernando J, Gimeno Collado A.
    Arch Esp Urol; 2000 May 15; 53(4):333-41. PubMed ID: 10900763
    [Abstract] [Full Text] [Related]

  • 16. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
    Romppanen J, Haapalainen T, Punnonen K, Penttilä I.
    Anticancer Res; 2002 May 15; 22(1A):415-20. PubMed ID: 12017325
    [Abstract] [Full Text] [Related]

  • 17. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X, Truan D, Alcover J, Quintó L, Molina R, Luque P, Coca F, Ballesta AM.
    Urology; 2004 Jun 15; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [Abstract] [Full Text] [Related]

  • 18. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H, Kajita Y, Shimizu Y, Yamauchi T.
    Hinyokika Kiyo; 2001 Mar 15; 47(3):169-74. PubMed ID: 11329957
    [Abstract] [Full Text] [Related]

  • 19. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
    Pannek J, Rittenhouse HG, Evans CL, Finlay JA, Bruzek DJ, Cox JL, Chan DW, Subong EN, Partin AW.
    Urology; 1997 Nov 15; 50(5):715-21. PubMed ID: 9372881
    [Abstract] [Full Text] [Related]

  • 20. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 15; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.